Intuitive Surgical SVP Patricia Wadors sells $478,416 in shares

Patricia L. Wadors, SVP Chief Human Resources Officer at Intuitive Surgical Inc. (NASDAQ:ISRG), sold 1,078 shares of the company’s common stock for a total value of $478,416. The transaction occurred on October 23, 2026.

The shares were sold at a price of $443.80 each. The stock has since risen to $450.79, with Intuitive Surgical commanding a market capitalization of $156.3 billion as a prominent player in the Healthcare Equipment & Supplies industry. This sale was conducted in accordance with a pre-arranged trading plan, known as a Rule 10b5-1 plan, which is scheduled to expire on May 29, 2027. According to InvestingPro analysis, the stock trades near its Fair Value, though at a high P/E ratio of 54.16. Investors can access 15 additional ProTips and comprehensive financial metrics on InvestingPro.

In other recent news, Intuitive Surgical reported third-quarter revenue of $3.05 billion, surpassing both Oppenheimer’s estimate of $2.92 billion and the consensus expectation of $2.91 billion. However, the company’s GAAP earnings per share were $1.49, falling short of Oppenheimer’s projection of $2.38 and the consensus of $2.39, due to a $450 million litigation settlement. The company’s performance was bolstered by strong results in its Systems, Services, and Instruments & Accessories segments, with Systems revenue reaching $769 million compared to the Street estimate of $679 million.

In the realm of analyst ratings, RBC Capital lowered its price target for Intuitive Surgical to $550 from $575, citing concerns over U.S. volume growth, which slowed to 10% from 12% in the second quarter. Meanwhile, Truist Securities maintained a Buy rating with a $510 price target, noting significant capital demand and a 40% increase in net da Vinci placements. Stifel also reiterated its Buy rating with a $550 price target after the company exceeded consensus revenue and earnings projections. Mizuho, on the other hand, reduced its price target to $400 from $415, maintaining a Neutral rating amid concerns about procedure growth slowdown.